Overview

Glucophage Immediate Release (GIR) China Bioequivalence Study

Status:
Completed
Trial end date:
2018-01-29
Target enrollment:
Participant gender:
Summary
The study will assess the bioequivalence between single doses of glucophage immediate release (GIR) test tablets and GIR reference tablets under fed and fasted state in healthy subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Merck KGaA, Darmstadt, Germany
Treatments:
Metformin